Genewity is pioneering advanced technologies aimed at revolutionising immune reconstitution for patients with severe immune deficiencies. In close collaboration with world-leading institutions and industry partners, we focus on rigorous preclinical and clinical research to deliver transformative therapies that restore immune function. Our innovative solutions leverage gene-modified cell therapies to address complex immune disorders, ultimately enhancing patient well-being and healthcare outcomes. With a commitment to scientific excellence and patient-centric care, Genewity is at the forefront of transforming the future of immunotherapy.

Revolutionising immune reconstitution with autologous thymus tissue

For a simplified version of this explanation, click here.

The thymus is a small organ located above the heart that plays a key role in developing a balanced immune system, especially in the development of functional T-cells. Similar to SCID, for children born without a functioning thymus, even common illnesses like the flu can become life-threatening, since T-cells do not develop without the thymus. On the other hand, if the thymus promotes excessive immune activity, it can lead to autoimmune disorders, where the immune system mistakenly attacks the body's own tissues.

Unfortunately, no thymic stem cells exist to regenerate the thymus, and thymic cells cannot be cultured ex vivo. This presents a significant challenge for patients with immune dysfunctions where traditional therapeutic options are limited. At Genewity, we have developed a proprietary technology that addresses this unmet need: i-Thymus. By introducing a master transcription factor into patient-derived induced pluripotent stem cells (iPSCs), we can differentiate autologous cells into functional thymic organoids for the replacement of thymic function without the limitations of donor tissue.

The ability to generate thymic organoids from a patient’s own cells positions Genewity as a leader in the field of immune reconstitution. The i-Thymus platform offers a patient-specific solution to address immune dysfunction, targeting severeconditions (e.g. congenital athymia) where T-cell immunity needs to be switched ON, but also autoimmune diseases, where T-cell immunity needs to be switched OFF.

In autoimmune disease, we are striving to restore immune tolerance by harnessing the thymus' natural ability to induce apoptosis in auto-reactive T-cells and promote the development of regulatory T-cells. Based on the i-Thymus platform, we are creating specialised thymus tissue (i-TOL) to reprogram the patient’s immune system toward a tolerogenic state, offering a promising new avenue for treating autoimmune diseases.